---
category: news
title: "The CEO of a $1.6 billion biotech says his bet on AI is paying off with faster, cheaper research that could reshape the industry"
excerpt: "Recursion says it can get drugs to the start of human testing at only 20% of the average cost while vetting potential treatments twice as fast."
publishedDateTime: 2023-01-25T14:30:00Z
originalUrl: "https://www.businessinsider.com/recursion-pharmaceuticals-ceo-interview-ai-in-biotech-2023-outlook-2023-1"
webUrl: "https://www.businessinsider.com/recursion-pharmaceuticals-ceo-interview-ai-in-biotech-2023-outlook-2023-1"
type: article

provider:
  name: Business Insider
  domain: businessinsider.com
  images:
    - url: "https://everyday-cc.github.io/ai/assets/images/organizations/businessinsider.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - AI

secured: "46EK0wTdkGHFxWJEZ9JKsmuYtYLDlquWXf80manc41+TLHFa6SaBM0iaSfjt42PMFBPZkPrEczwEjeNkEFSMEYeFDlfTmFs82gpu1XDgCPxXAE6+DiQM7q5TlUuQfONqpDPrJDmB3qz8rzYWNARg7Ii1FzmMWmOpwhrm1CcWyCK92X2gkKHOq9f32A3vo+4OWl5FhQSbwUWF68WlbVedUMgfM3dTsI03ce6c+TRxglR8TC7BdJ7/7eui6YzmQW7ewLQqKNhQjw6SvS5cwkTjhV2hHazikfOjTwlfwhzRTKV7lwpdbLPVa1j+Lucv/G9BaDL726LcyeIc4v0A3kCUPtOQ3hddKNMsS6UnLmEMq68=;eVt9hqz+YyT+eTJaScJCcA=="
---

